Dangle Pankaj P, Ayyash Omar, Kang Audry, Bates Carlton, Fox Janelle, Stephany Heidi, Cannon Glenn
Division of Pediatric Urology, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA.
Division of Pediatric Urology, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA.
Urology. 2017 Feb;100:213-217. doi: 10.1016/j.urology.2016.08.011. Epub 2016 Aug 16.
To asses if cystatin c-calculated glomerular filtration rate (GFR) can reveal chronic kidney disease (CKD) not detected by creatinine-based calculations in a larger prospective cohort of children with myelomeningocele (MMC). Wheelchair-bound MMC patients frequently have low muscle mass, and assessing renal deterioration based on creatinine-based GFR is imprecise. MMC patients are also at risk for end-stage renal disease.
Prospectively enrolled patients with MMC underwent annual serum creatinine and cystatin c testing. Anthropometric measurements were obtained from clinic visit. The modified (bedside) Schwartz formula for creatinine-based GFR and the Zappitelli cystatin C formula were utilized for calculation. The exclusion criteria were patients with reduced GFR (CKD stage 2) or chronic CKD (CKD stage 3 and greater); these patients were excluded from analysis on the premise that they had already been identified for closer renal monitoring.
A total of 131 patients were included in the analysis. The median creatinine-based estimated GFR was 126.5 mL/min/1.73 m (range: 22-310). The median cystatin C-based estimated rate was 98.5 mL/min/1.73 m (range: 16-171), yielding an absolute median rate reduction of 30.2%. Using cystatin c-calculated GFR, CKD stage was upgraded from stage 1 to ≥2 in 34 patients (26%).
In MMC patients with poor muscle mass, cystatin C-based GFR is more sensitive than creatinine-based GFR in detecting early CKD. In this high-risk population, serial cystatin C estimation is a valuable tool in identifying children who may benefit from early nephrology referral and intervention.
评估在一个更大的脊髓脊膜膨出(MMC)患儿前瞻性队列中,基于胱抑素C计算的肾小球滤过率(GFR)能否揭示基于肌酐计算未检测出的慢性肾脏病(CKD)。需要轮椅辅助的MMC患者肌肉量常常较低,基于肌酐的GFR评估肾脏恶化情况并不精确。MMC患者也有患终末期肾病的风险。
前瞻性纳入的MMC患者每年接受血清肌酐和胱抑素C检测。人体测量数据来自临床就诊。基于肌酐的GFR采用改良(床边)Schwartz公式计算,胱抑素C采用Zappitelli公式计算。排除标准为GFR降低(CKD 2期)或慢性CKD(CKD 3期及以上)的患者;这些患者已被确定需进行更密切的肾脏监测,故被排除在分析之外。
共有131例患者纳入分析。基于肌酐的估计GFR中位数为126.5 mL/min/1.73 m²(范围:22 - 310)。基于胱抑素C的估计GFR中位数为98.5 mL/min/1.73 m²(范围:16 - 171),绝对中位数降低率为30.2%。使用基于胱抑素C计算的GFR,34例患者(26%)的CKD分期从1期升至≥2期。
在肌肉量少的MMC患者中,基于胱抑素C的GFR在检测早期CKD方面比基于肌酐的GFR更敏感。在这个高危人群中,连续检测胱抑素C是识别可能从早期肾病转诊和干预中获益儿童的有价值工具。